A study published in Science Translational Medicine shows that PGDx's CerebroTM technology can detect tumor-specific mutations with higher sensitivity and positive predictive value compared to existing methods. This improvement is crucial for accurate treatment decisions, particularly for biomarkers like tumor mutation burden.
A recent study published in Nature Communications presents a proof-of-concept for an oral, once-weekly drug delivery platform for HIV antiretroviral therapy. The platform demonstrates sustained oral delivery of potent anti-HIV therapies, offering a potential solution to non-adherence issues.
Researchers at eGenesis have successfully produced the first PERV-free piglets using CRISPR technology, addressing safety concerns in xenotransplantation. The breakthrough demonstrates the potential of gene editing to prevent cross-species viral transmission and pave the way for safe human transplantable cells, tissues, and organs.
A recent study published in Science used GemCode technology to analyze the biomedical consequences of adult humans with gene knockouts. The research revealed that PRDM9 redundancy in humans suggests that the gene may not be essential for human life, challenging previous assumptions.
Researchers demonstrate MYK-461's ability to prevent and reverse hypertrophic cardiomyopathy (HCM) in genetically modified mouse models. The study supports a therapeutic hypothesis that reducing sarcomere power output can improve structural pathology, potentially treating HCM.
Scientists have discovered new antifungal compounds that selectively kill pathogens without evoking drug resistance. These novel compounds were designed to act as molecular sponges for ergosterol, found exclusively on fungi surfaces, and exhibit undetectable binding to human cells.
Revolution Medicines has developed a unified 'building blocks' approach for synthesizing multiple classes of complex natural chemicals that could be valuable backbones for new medicines. The company's technology can produce a broad range of molecules, including those with diverse types of chemical bonds and highly complex cyclic struct...
A study published in Clinical Infectious Diseases demonstrated the pivotal data for T2Candida and T2Dx, detecting Candida species with 91.1% sensitivity and 99.4% specificity in 3-5 hours without blood culture. This technology has the potential to reduce costs, length of stay, and mortality rates associated with Candida infections.
Agios research shows that mutant IDH1 and IDH2 inhibitors can reverse cellular differentiation in patient-derived tumor samples, reducing the oncometabolite 2-HG levels. This provides promising preclinical support for targeted therapies against cancer-causing mutations.
The first high-quality reference genome of the domestic goat has been successfully assembled using OpGen's ARGUS Whole Genome Mapping System in combination with next-generation sequencing. The study demonstrates the efficiency and cost-effectiveness of this technology for large, complex genomes.
A Phase 1 study demonstrated galeterone's tolerability and efficacy in patients with castration-resistant prostate cancer, with minimal toxicities reported. The study showed significant reductions in tumor size and prostate-specific antigen levels in nearly half of the patients evaluated.
Researchers demonstrate the role of cellular bioenergetics in selectively inhibiting pathogenic lymphocytes while preserving normal immune function. Lycera's prototype compound Bz-423 induces selective apoptosis of alloreactive donor T cells, reversing graft-versus-host disease and improving survival in mice.
A Phase 3 trial showed patients receiving Probuphine had significantly less illicit opioid use and fewer withdrawal symptoms compared to placebo. The innovative implant formulation provided a steady, round-the-clock low dose of buprenorphine over six months.
A Phase 1/2 study of LentiGlobin gene therapy has demonstrated positive results in a young adult with severe beta-thalassemia, achieving transfusion independence for over two years. The treatment also identified cells with the corrected beta-globin gene that overexpressed HMGA2.
AVEO scientists have developed a novel human-in-mouse (HIM) cancer model system, which allows for the creation of invasive human tumors that mimic human tumor behaviors and response. The models provide a more realistic genetic context for evaluating new anti-tumor therapies.
A new review article highlights the potential of sirtuins to treat diseases of aging such as Type 2 Diabetes and mitochondrial disorders. Early clinical studies suggest that SIRT1 activation may lower glucose and improve insulin sensitivity.
A Phase 2 trial of PTC124 demonstrated statistically significant improvements in CFTR-mediated chloride transport and lung function in patients with nonsense-mutation CF. The study showed that PTC124 induced chloride transport responses across various patient genotypes, offering a potential new treatment paradigm for this genetic disease.
A long-term study shows that resveratrol improves bone health, reduces cataracts and cardiovascular dysfunction, and enhances balance and motor coordination in middle-aged mice. The study also found that resveratrol induces gene expression patterns similar to those induced by dietary restriction.
Scientists at Sirtris developed potent SIRT1 activators, 1000 times more effective than resveratrol, to treat Type 2 Diabetes and age-related diseases. These findings hold promise for a new approach to treating metabolic and other diseases of aging.